Literature DB >> 10835005

Correlation between in vitro and in vivo antifungal activities in experimental fluconazole-resistant oropharyngeal and esophageal candidiasis.

T J Walsh1, C E Gonzalez, S Piscitelli, J D Bacher, J Peter, R Torres, D Shetti, V Katsov, K Kligys, C A Lyman.   

Abstract

Oropharyngeal and esophageal candidiasis (OPEC) is a frequent opportunistic mycosis in immunocompromised patients. Azole-resistant OPEC is a refractory form of this infection occurring particularly in human immunodeficiency virus (HIV)-infected patients. The procedures developed by the Antifungal Subcommittee of the National Committee for Clinical Laboratory Standards (NCCLS) are an important advance in standardization of in vitro antifungal susceptibility methodology. In order to further understand the relationship between NCCLS methodology and antifungal therapeutic response, we studied the potential correlation between in vitro susceptibility to fluconazole and in vivo response in a rabbit model of fluconazole-resistant OPEC. MICs of fluconazole were determined by NCCLS methods. Three fluconazole-susceptible (FS) (MIC, </=0.125 microgram/ml) and three fluconazole-resistant (FR) (MIC, >/=64 microgram/ml) isolates of Candida albicans from prospectively monitored HIV-infected children with OPEC were studied. FR isolates were recovered from children with severe OPEC refractory to fluconazole, and FS isolates were recovered from those with mucosal candidiasis responsive to fluconazole. Fluconazole at 2 mg/kg of body weight/day was administered to infected animals for 7 days. The concentrations of fluconazole in plasma were maintained above the MICs for FS isolates throughout the dosing interval. Fluconazole concentrations in the esophagus were greater than or equal to those in plasma. Rabbits infected with FS isolates and treated with fluconazole had significant reductions in oral mucosal quantitative cultures (P < 0.001) and tissue burden of C. albicans in tongue, soft palate, and esophagus (P < 0.001). In comparison, rabbits infected with FR isolates were unresponsive to fluconazole and had no reduction in oral mucosal quantitative cultures or tissue burden of C. albicans versus untreated controls. We conclude that there is a strong correlation between in vitro fluconazole susceptibility by NCCLS methods and in vivo response to fluconazole therapy of OPEC due to C. albicans.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10835005      PMCID: PMC86806          DOI: 10.1128/JCM.38.6.2369-2373.2000

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  24 in total

Review 1.  Resistance of Candida species to fluconazole.

Authors:  J H Rex; M G Rinaldi; M A Pfaller
Journal:  Antimicrob Agents Chemother       Date:  1995-01       Impact factor: 5.191

2.  Comparative resistance of Candida albicans clinical isolates to fluconazole and itraconazole in vitro and in vivo in a murine model.

Authors:  A Valentin; R Le Guennec; E Rodriguez; J Reynes; M Mallie; J M Bastide
Journal:  Antimicrob Agents Chemother       Date:  1996-06       Impact factor: 5.191

3.  Variation in fluconazole efficacy for Candida albicans strains sequentially isolated from oral cavities of patients with AIDS in an experimental murine candidiasis model.

Authors:  F Barchiesi; L K Najvar; M F Luther; G Scalise; M G Rinaldi; J R Graybill
Journal:  Antimicrob Agents Chemother       Date:  1996-05       Impact factor: 5.191

4.  In vitro activities of semisynthetic pneumocandin L-733,560 against fluconazole-resistant and -susceptible Candida albicans isolates.

Authors:  J V Martinez-Suarez; J L Rodriguez-Tudela
Journal:  Antimicrob Agents Chemother       Date:  1996-05       Impact factor: 5.191

5.  Correlation between in vitro and in vivo activity of antifungal agents against Candida species.

Authors:  E J Anaissie; N C Karyotakis; R Hachem; M C Dignani; J H Rex; V Paetznick
Journal:  J Infect Dis       Date:  1994-08       Impact factor: 5.226

6.  Detection and significance of fluconazole resistance in oropharyngeal candidiasis in human immunodeficiency virus-infected patients.

Authors:  S G Revankar; W R Kirkpatrick; R K McAtee; O P Dib; A W Fothergill; S W Redding; M G Rinaldi; T F Patterson
Journal:  J Infect Dis       Date:  1996-10       Impact factor: 5.226

7.  Epidemiology of oral candidiasis in HIV-infected patients: colonization, infection, treatment, and emergence of fluconazole resistance.

Authors:  J A Sangeorzan; S F Bradley; X He; L T Zarins; G L Ridenour; R N Tiballi; C A Kauffman
Journal:  Am J Med       Date:  1994-10       Impact factor: 4.965

8.  Emergence of azole drug resistance in Candida species from HIV-infected patients receiving prolonged fluconazole therapy for oral candidosis.

Authors:  E M Johnson; D W Warnock; J Luker; S R Porter; C Scully
Journal:  J Antimicrob Chemother       Date:  1995-01       Impact factor: 5.790

9.  Risk factors for fluconazole-resistant candidiasis in human immunodeficiency virus-infected patients.

Authors:  J R Maenza; J C Keruly; R D Moore; R E Chaisson; W G Merz; J E Gallant
Journal:  J Infect Dis       Date:  1996-01       Impact factor: 5.226

10.  Fluconazole concentrations in saliva from AIDS patients with oropharyngeal candidosis refractory to treatment with fluconazole.

Authors:  D Garcia-Hermoso; F Dromer; L Improvisi; F Provost; B Dupont
Journal:  Antimicrob Agents Chemother       Date:  1995-03       Impact factor: 5.191

View more
  15 in total

Review 1.  In vivo pharmacodynamics of antifungal drugs in treatment of candidiasis.

Authors:  David Andes
Journal:  Antimicrob Agents Chemother       Date:  2003-04       Impact factor: 5.191

2.  Dosage-dependent antifungal efficacy of V-echinocandin (LY303366) against experimental fluconazole-resistant oropharyngeal and esophageal candidiasis.

Authors:  V Petraitis; R Petraitiene; A H Groll; T Sein; R L Schaufele; C A Lyman; A Francesconi; J Bacher; S C Piscitelli; T J Walsh
Journal:  Antimicrob Agents Chemother       Date:  2001-02       Impact factor: 5.191

3.  Activity of potent and selective host defense peptide mimetics in mouse models of oral candidiasis.

Authors:  Lisa K Ryan; Katie B Freeman; Jorge A Masso-Silva; Klaudia Falkovsky; Ashwag Aloyouny; Kenneth Markowitz; Amy G Hise; Mahnaz Fatahzadeh; Richard W Scott; Gill Diamond
Journal:  Antimicrob Agents Chemother       Date:  2014-04-21       Impact factor: 5.191

4.  Prevalence of molecular mechanisms of resistance to azole antifungal agents in Candida albicans strains displaying high-level fluconazole resistance isolated from human immunodeficiency virus-infected patients.

Authors:  S Perea; J L López-Ribot; W R Kirkpatrick; R K McAtee; R A Santillán; M Martínez; D Calabrese; D Sanglard; T F Patterson
Journal:  Antimicrob Agents Chemother       Date:  2001-10       Impact factor: 5.191

5.  Possible inhibitory molecular mechanism of farnesol on the development of fluconazole resistance in Candida albicans biofilm.

Authors:  Li-Hua Yu; Xin Wei; Ming Ma; Xiao-Jun Chen; Shuang-Bo Xu
Journal:  Antimicrob Agents Chemother       Date:  2011-11-21       Impact factor: 5.191

6.  Randomized, double-blind, multicenter study of caspofungin versus amphotericin B for treatment of oropharyngeal and esophageal candidiases.

Authors:  Eduardo G Arathoon; Eduardo Gotuzzo; L Miguel Noriega; Rayanne S Berman; Mark J DiNubile; Carole A Sable
Journal:  Antimicrob Agents Chemother       Date:  2002-02       Impact factor: 5.191

Review 7.  Immunopathogenesis of oropharyngeal candidiasis in human immunodeficiency virus infection.

Authors:  Louis de Repentigny; Daniel Lewandowski; Paul Jolicoeur
Journal:  Clin Microbiol Rev       Date:  2004-10       Impact factor: 26.132

8.  New model of oropharyngeal candidiasis in mice.

Authors:  Y Kamai; M Kubota; Y Kamai; T Hosokawa; T Fukuoka; S G Filler
Journal:  Antimicrob Agents Chemother       Date:  2001-11       Impact factor: 5.191

9.  Efficacy of PLD-118, a novel inhibitor of candida isoleucyl-tRNA synthetase, against experimental oropharyngeal and esophageal candidiasis caused by fluconazole-resistant C. albicans.

Authors:  Vidmantas Petraitis; Ruta Petraitiene; Amy M Kelaher; Alia A Sarafandi; Tin Sein; Diana Mickiene; John Bacher; Andreas H Groll; Thomas J Walsh
Journal:  Antimicrob Agents Chemother       Date:  2004-10       Impact factor: 5.191

10.  Oral lactoferrin treatment of experimental oral candidiasis in mice.

Authors:  Natsuko Takakura; Hiroyuki Wakabayashi; Hiroko Ishibashi; Susumu Teraguchi; Yoshitaka Tamura; Hideyo Yamaguchi; Shigeru Abe
Journal:  Antimicrob Agents Chemother       Date:  2003-08       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.